Gilead Signs an Agreement with Carna Biosciences to Develop and Commercialize Immuno-Oncology Therapies

 Gilead Signs an Agreement with Carna Biosciences to Develop and Commercialize Immuno-Oncology Therapies

Gilead Signs an Agreement with Carna Biosciences to Develop and Commercialize Immuno-Oncology Therapies

Shots:

  • Carna to receive $20M upfront, up to $450M as development & commercial milestones and royalties on sales. Gilead to get WW rights to develop and commercialize inhibitors against immuno-oncology target and an exclusive right to access Carna’s lipid kinase drug discovery platform
  • The focus of the collaboration is to advance novel immunotherapies targeting cancer by utilizing Carna’s lipid kinase drug discovery platform
  • Carna Biosciences focuses on developing kinase inhibitors targeting oncology, autoimmune and neurological diseases by inhibiting kinases which are important drivers for the diseases

Click here to read full press release/ article | Ref: Gilead | Image: Atelier Ten

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post